Enliven Therapeutics, Inc. - 8-K Filing
Enliven Therapeutics appoints Kristine Ball as a Class II director with compensation of $55,000 annually and stock options valued at approximately $650,000. (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits (d) Exhibits See the Exhibit Index below, which is incorporated by reference herein)
Tickers: $ELVN